Therapeutic Response Statement (Sensitivity)
This therapeutic response statement supports the relationship that HER2-negative status confers therapeutic sensitivity to Cisplatin, Fluorouracil, Pembrolizumab in patients with Adenocarcinoma of the Gastroesophageal Junction.
This statement is based on a regulatory approval from the Health Canada:
KEYTRUDA (pembrolizumab), in combination with fluoropyrimidine- and platinum-containing chemotherapy, is indicated for the first-line treatment of adult patients with locally advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma.